Observational studyClinical nuclear medicine2026

Outcome and Safety of Radioligand Therapy With [ 161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [ 177 Lu]Lu-PSMA-617.

Florian Rosar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.